Last reviewed · How we verify
Leucostim 5µg/kg/day
Leucostim is a granulocyte colony-stimulating factor (G-CSF) that stimulates the proliferation and differentiation of neutrophil precursor cells in bone marrow.
Leucostim is a granulocyte colony-stimulating factor (G-CSF) that stimulates the proliferation and differentiation of neutrophil precursor cells in bone marrow. Used for Chemotherapy-induced neutropenia, Severe chronic neutropenia, Mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation.
At a glance
| Generic name | Leucostim 5µg/kg/day |
|---|---|
| Sponsor | Dong-A ST Co., Ltd. |
| Drug class | Granulocyte colony-stimulating factor (G-CSF) |
| Target | G-CSF receptor (CSF3R) |
| Modality | Biologic |
| Therapeutic area | Oncology, Hematology, Immunology |
| Phase | Phase 3 |
Mechanism of action
G-CSF binds to G-CSF receptors on hematopoietic progenitor cells, promoting their growth, differentiation, and functional activation. This increases circulating neutrophil counts, enhancing immune function and reducing infection risk in patients with neutropenia or undergoing chemotherapy.
Approved indications
- Chemotherapy-induced neutropenia
- Severe chronic neutropenia
- Mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation
Common side effects
- Bone pain
- Headache
- Fatigue
- Injection site reactions
- Splenomegaly
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Leucostim 5µg/kg/day CI brief — competitive landscape report
- Leucostim 5µg/kg/day updates RSS · CI watch RSS
- Dong-A ST Co., Ltd. portfolio CI